AFP and hepatocellular carcinoma: suggested that in high‐risk populations, the combination of CTC‐scoring assays with the standard serum biomarker α‐fetoprotein (AFP) may offer higher specificity and sensitivity required for hepatocellular carcinoma (HCC) screening, which AFP alone is unable to provide.